A Clinically Relevant BTX-A Injection Protocol Leads to Persistent Weakness, Contractile Material Loss, and an Altered mRNA Expression Phenotype in Rabbit Quadriceps Muscles

Botulinum toxin type-A (BTX-A) injections have become a common treatment modality for patients suffering from muscle spasticity. Despite its benefits, BTX-A treatments have been associated with adverse effects on target muscles. Currently, application of BTX-A is largely based on clinical experience, and research quantifying muscle structure following BTX-A treatment has not been performed systematically. The purpose of this study was to evaluate strength, muscle mass, and contractile material six months following a single or repeated (2 and 3) BTX-A injections into the quadriceps femoris of New Zealand white rabbits.
Source: Journal of Biomechanics - Category: Biomedical Science Authors: Source Type: research